Whether the convenience of a daily pill will outweigh the discipline required to take it on an empty stomach each morning remains to be seen, but for patients deterred by needles or seeking lower costs, Novo Nordisk’s bet on oral semaglutide could reshape how millions approach weight loss treatment.
Novo Nordisk has began distributing the first oral GLP-1 medication approved for weight loss in the United States, offering patients an alternative to weekly injections that have dominated the obesity treatment market.
The Danish pharmaceutical company’s Wegovy pill received Food and Drug Administration approval on Dec. 22, making it the first oral glucagon-like peptide-1 receptor agonist cleared for chronic weight management.
The starting dose of 1.5 milligrams is now available at more than 70,000 pharmacies nationwide, including CVS and Costco, with higher doses arriving by week’s end.
Clinical Trial Results Show Comparable Efficacy
In the OASIS 4 phase 3 clinical trial, participants taking the highest 25-milligram dose of oral semaglutide achieved 16.6 percent mean weight loss over 64 weeks when adhering to the treatment regimen, compared with 2.7 percent for those receiving a placebo.
The study, which involved 307 adults with obesity or overweight with weight-related health conditions but without diabetes, showed weight loss comparable to the injectable version of Wegovy.
According to research published in The New England Journal of Medicine, patients who remained on treatment throughout the trial period lost approximately 17 percent of their body weight, with one-third achieving at least 20 percent weight reduction.
The pill shares the same active ingredient, semaglutide, as Novo Nordisk’s injectable Wegovy and diabetes medication Ozempic. Both formulations work by mimicking the gut hormone GLP-1 to suppress appetite.
Pricing Structure and Access
The company is offering the lowest 1.5-milligram starter dose at $149 per month for cash-paying patients, significantly lower than the roughly $1,000 monthly cost of injectable GLP-1 medications.
The 4-milligram dose carries the same price through April 15, after which it will increase to $199. Higher doses of 9 milligrams and 25 milligrams are priced at $299 monthly.
Patients with insurance coverage may pay as little as $25 per month through Novo Nordisk’s savings program. The list price for insurers remains $1,349 monthly, matching the injectable version.
The pricing reflects a deal Novo Nordisk struck with the Trump administration in November to make the medication available through a direct-to-consumer website called TrumpRx, set to launch this month.
Practical Considerations
The oral medication requires patients to take it first thing in the morning on an empty stomach with no more than four ounces of water, then wait 30 minutes before eating or drinking. This strict timing requirement differs from the weekly injection schedule.
Dr. Shauna Levy, medical director of the Tulane Weight Loss Center, told NBC News that adherence to this schedule will likely be the biggest challenge, noting that trial participants who did not follow the timing protocol experienced less weight loss.
Side effects mirror those of the injectable version, including nausea, diarrhea and vomiting. Some physicians have noted that gastrointestinal symptoms may feel more intense with the pill because the medication enters the stomach all at once.
Market Competition
The pill launch comes as Novo Nordisk seeks to regain market share lost to rival Eli Lilly, whose Zepbound injection has largely led in weekly U.S. prescriptions over the past year.
Eli Lilly applied to the FDA in late 2025 for approval of its competing obesity pill, orforglipron, which received a priority review voucher. The agency is expected to make a decision by March 2026. In clinical trials, orforglipron showed average weight loss of approximately 12.4 percent over 72 weeks.
The oral medication also carries FDA approval to reduce the risk of major cardiovascular events, including death, heart attack or stroke, in adults with obesity or overweight and established cardiovascular disease, consistent with the injectable Wegovy’s indications.
Novo Nordisk has been manufacturing the pill at its North Carolina facilities and says it has robust supply on hand to avoid the shortages that plagued the injectable version after its 2021 launch.
Get the latest news and insights that are shaping the world. Subscribe to Impact Newswire to stay informed and be part of the global conversation.
Got a story to share? Pitch it to us at info@impactnews-wire.com and reach the right audience worldwide
Discover more from Impact AI News
Subscribe to get the latest posts sent to your email.
